Cardiol Therapeutics (STU:CT9) Change In Receivables: €-0.02 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:CT9 Cardiol Therapeutics Inc STU:CT9
34 GF Score
Price €1.56
! 4 Warning Signs
View Full Analysis

What is Cardiol Therapeutics Change In Receivables?

Cardiol Therapeutics STU:CT9 -1.76% 34 Change In Receivables is €-0.02 Mil as of Jun. 2026. GuruFocus rates STU:CT9 with a GF Score™ of 34/100. The stock has 4 warning signs investors should review.

Cardiol Therapeutics's change in receivables for the quarter that ended in Jun. 2026 was €0.02 Mil. It means Cardiol Therapeutics's Accounts Receivable declined by €0.02 Mil from Mar. 2026 to Jun. 2026 .

Cardiol Therapeutics's change in receivables for the fiscal year that ended in Dec. 2025 was €0.08 Mil. It means Cardiol Therapeutics's Accounts Receivable declined by €0.08 Mil from Dec. 2024 to Dec. 2025 .

Cardiol Therapeutics's Accounts Receivable for the quarter that ended in Jun. 2026 was €0.04 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Cardiol Therapeutics's liquidation value for the three months ended in Jun. 2026 was €12.87 Mil.

Cardiol Therapeutics  (STU:CT9) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Cardiol Therapeutics's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.04/0*91
=

2. In Ben Graham's calculation of liquidation value, Cardiol Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Cardiol Therapeutics's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=16.131-3.296+0.75 * 0.04+0.5 * 0
=12.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiol Therapeutics Change In Receivables Related Terms

Cardiol Therapeutics Change In Receivables Historical Data

* Premium members only.

The historical data trend for Cardiol Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiol Therapeutics Change In Receivables Chart

Cardiol Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only -0.13 -0.05 0.14 -0.06 0.08

Cardiol Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.05 -0.02 -0.07 0.02
STU:CT9
34GF Score
Cardiol Therapeutics Inc STU:CT9
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cardiol Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of €-0.02 Mil mean?
Cardiol Therapeutics (STU:CT9) has a Change In Receivables of €-0.02 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Cardiol Therapeutics and its competitors.
Is Cardiol Therapeutics' Change In Receivables too high?
Cardiol Therapeutics' current Change In Receivables is €-0.02 Mil. Overall, Cardiol Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Cardiol Therapeutics' Change In Receivables compare to ZTS?
Cardiol Therapeutics' Change In Receivables of €-0.02 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Drug Manufacturers company?
A good Change In Receivables depends on the Drug Manufacturers industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Cardiol Therapeutics and its competitors. Cardiol Therapeutics's current Change In Receivables is €-0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiol Therapeutics stock overvalued right now?
Cardiol Therapeutics (STU:CT9) has a current Change In Receivables of €-0.02 Mil. The current Change In Receivables is €-0.02 Mil. Cardiol Therapeutics' overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Cardiol Therapeutics (STU:CT9), the current Change In Receivables is €-0.02 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cardiol Therapeutics Business Description

Other Exchanges CRDL:USACRDL:Canada
Address 2265 Upper Middle Road East, Suite 602, Oakville, ON, CAN, L6H 0G5
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
34GF Score

Get the complete analysis for STU:CT9

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.56
Price